Cytarabine: all 556 studies that test it

Page 3 of 6. Open to participants first (82), then studies with results posted, then the rest; newest registration first within each.

• Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma PatientsCompletedNCT00577993Phase 3Results posted
• Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins LymphomaCompletedNCT00577629Phase 2Results posted
• Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)CompletedNCT00569010Phase 1/2Results posted
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00558519Phase 2Results posted
• Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic LeukemiaCompletedNCT00549848Phase 3Results posted
• Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)CompletedNCT00542971Phase 1/2Results posted
• Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in HumansCompletedNCT00541866Phase 1/2Results posted
• Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00528398Phase 2Results posted
• DepoCyt for Active Lymphomatous or Leukemic MeningitisTerminatedNCT00523939Phase 2Results posted
• A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.TerminatedNCT00517699Phase 2Results posted
• AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid LeukemiaCompletedNCT00512252Phase 1/2Results posted
• Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00503880Phase 1/2Results posted
• Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)TerminatedNCT00480987Phase 1/2Results posted
• Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell LymphomaCompletedNCT00477412Phase 1/2Results posted
• ALL Adult Consortium Trial: Adult ALL TrialCompletedNCT00476190Phase 2Results posted
• Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and LeukemiasCompletedNCT00472849Phase 1/2Results posted
• Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's SarcomaCompletedNCT00470275Phase 2Results posted
• Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00469859Phase 1/2Results posted
• Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLLCompletedNCT00452374Phase 1/2Results posted
• R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell LymphomaCompletedNCT00450801Phase 2Results posted
• Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)CompletedNCT00422591Phase 2Results posted
• Study of VELCADE® With Mitoxantrone and Etoposide for LeukemiasCompletedNCT00410423Phase 1/2Results posted
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaCompletedNCT00408005Phase 3Results posted
• Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00407966Phase 2Results posted
• Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) PatientsCompletedNCT00382590Phase 2Results posted
• Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00372619Phase 1/2Results posted
• Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00369317Phase 3Results posted
• T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell GraftsCompletedNCT00368355Phase 2Results posted
• Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's LymphomaCompletedNCT00345865Phase 2Results posted
• S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT00337168Phase 2Results posted
• Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaCompletedNCT00333840Phase 3Results posted
• Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's LymphomaCompletedNCT00302003Phase 3Results posted
• Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell LymphomaCompletedNCT00290433Phase 2Results posted
• Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic CancerTerminatedNCT00281879Phase 2Results posted
• Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT00186875Phase 2Results posted
• CINJALL: Treatment for Children With Acute Lymphocytic LeukemiaCompletedNCT00176462Phase 2Results posted
• Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins LymphomaCompletedNCT00166439Phase 2Results posted
• Therapy for Newly Diagnosed Patients With Acute Lymphoblastic LeukemiaCompletedNCT00137111Phase 3Results posted
• Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or MyelodysplasiaCompletedNCT00136084Phase 3Results posted
• S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00109837Phase 2Results posted
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00103285Phase 3Results posted
• Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or TestesCompletedNCT00096135Not applicableResults posted
• Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT00096122Phase 1/2Results posted
• Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).CompletedNCT00088218Phase 2Results posted
• Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RTCompletedNCT00084838Phase 2Results posted
• Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00078949Phase 3Results posted
• Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)CompletedNCT00067028Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00054327Phase 2Results posted
• S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell LymphomaCompletedNCT00041132Phase 2Results posted
• Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's DiseaseCompletedNCT00025259Phase 3Results posted
• Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00022490Phase 2Results posted
• Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid CancerCompletedNCT00014495Phase 1/2Results posted
• Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory LymphomaCompletedNCT00005803Phase 1/2Results posted
• Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's LymphomaCompletedNCT00003631Phase 2Results posted
• FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid NeoplasmsActive, not recruitingNCT06858618Phase 2
• Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT06504199Phase 2
• A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute LeukemiasWithdrawnNCT06474663Phase 1
• Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT06068621Phase 2
• Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid LeukemiaCompletedNCT05941585Not applicable
• Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid LeukemiaCompletedNCT05906914Phase 2
• Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive InductionWithdrawnNCT05766514Phase 2
• A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDSWithdrawnNCT05456269Phase 1
• Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid LeukemiaStatus unknownNCT05362942Phase 2
• GM-CLAG in Relapsed/Refractory FLT3-mutated AMLWithdrawnNCT05330377Phase 1
• A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to TreatWithdrawnNCT05320380Phase 1/2
• Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)CompletedNCT05319587Phase 1/2
• Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT05228249Phase 1
• Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AMLActive, not recruitingNCT05177731Phase 3
• Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AMLStatus unknownNCT05053425Not applicable
• Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.Status unknownNCT05049473Phase 2
• Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT04956042Phase 1/2
• Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaWithdrawnNCT04845035Phase 2
• Venetoclax + Azacitidine vs. Induction Chemotherapy in AMLActive, not recruitingNCT04801797Phase 2
• Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years OldCompletedNCT04687761Phase 1/2
• Risk-adapted Therapy for Primary Acute Myeloid LeukemiaCompletedNCT04687098Phase 2
• A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological MalignanciesActive, not recruitingNCT04547049Phase 3
• Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in AdultsActive, not recruitingNCT04530565Phase 3
• Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory LeukemiaTerminatedNCT04526795Phase 1
• Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural MesotheliomaCompletedNCT04525859Phase 1
• A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)CompletedNCT04509622Phase 3
• Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AMLStatus unknownNCT04254640Phase 2
• Trial Testing Safety of IL-21 NK Cells for Induction of R/R AMLCompletedNCT04220684Phase 1
• Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid NeoplasmsTerminatedNCT04196010Phase 1
• Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04190550Phase 1
• AraC for Newly Diagnosed Adult Langerhans Cell HistiocytosisStatus unknownNCT04121819Phase 2
• A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT04115631Phase 2
• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)TerminatedNCT04113616Phase 1/2
• Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60Status unknownNCT04083911Phase 3
• Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT03983824Phase 1
• A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaActive, not recruitingNCT03914625Phase 3
• Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaCompletedNCT03900949Phase 1
• Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin LymphomaCompletedNCT03892421Phase 1/2
• DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaStatus unknownNCT03837873Phase 2
• Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialTerminatedNCT03735446Phase 1
• Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell LymphomaWithdrawnNCT03719560Phase 2
• A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E MutationStatus unknownNCT03585686Phase 2
• A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell ReinfusionStatus unknownNCT03570983Phase 2
• EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute LeukemiaTerminatedNCT03519984Phase 1
• Epacadostat, Cladribine and Cytarabine (ECC) in AMLWithdrawnNCT03491579Phase 1
• CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALLActive, not recruitingNCT03467256Phase 1/2

← Cytarabine overview